Depression: A somber issue for women

Current Health Sees Care-at-Home Opportunities in High-Risk Pregnancies

Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.

Jared Kaltwasser

FDA Approves First Nonprescription Oral Contraceptive

Improving patient monitoring through care-at-home services could help reduce maternal mortality, they say.

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

Opill will be available in stores and online in the first quarter of 2024.

FDA Approves Second Indication for Brexafemme

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

FDA Approves Liletta IUD to Prevent Pregnancy for 8 Years

Brexafemme is a non-azole oral antifungal now approved to both treat and prevent recurrent yeast infections in women.

Lack of Diversity in Clinical Trials Hurts Research, and Costs Billions | AHA Scientific Sessions

The approval extends the use of Liletta for an additional two years. It is the only hormonal IUD approved for continuous use up to eight years.

Related Content

Ron Southwick

Current Health Sees Care-at-Home Opportunities in High-Risk Pregnancies

Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.

Jared Kaltwasser

FDA Approves First Nonprescription Oral Contraceptive

Improving patient monitoring through care-at-home services could help reduce maternal mortality, they say.

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

Opill will be available in stores and online in the first quarter of 2024.